Jonathan Cho
Hematology & Oncology · Honolulu, HINPI 1174590541
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,065 of the $2,593 with a category attached, or 79.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $976 and has fallen 67.8% since, to $314 in 2025.
Across 88 payments — averaging $29.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$424
- AbbVie$317
- E.r. Squibb & Sons, L.L.C.$223
- Medtronic$183
- Merck$174
- Pfizer$173
- plus $1K from 23 others
Across 7 payments — averaging $2699.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Puma Biotechnology, Inc.$19K
What the payments were for
- Food & beverage$2,06580%
- Education$52820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 7 | $424 |
| AbbVie | 9 | $317 |
| E.r. Squibb & Sons, L.L.C. | 5 | $223 |
| Medtronic | 1 | $183 |
| Merck | 14 | $174 |
| Pfizer | 12 | $173 |
| Caris MPI, Inc. | 1 | $156 |
| Geron Corporation | 1 | $123 |
| AstraZeneca | 1 | $107 |
| Johnson & Johnson | 4 | $106 |
| Amgen | 4 | $92 |
| Novo Nordisk | 3 | $59 |
| Genentech, Inc. | 3 | $57 |
| Seagen Inc. | 3 | $48 |
| Gilead(2 entities) | 3 | $46 |
| Puma Biotechnology, Inc. | 2 | $43 |
| Karyopharm Therapeutics Inc. | 1 | $35 |
| Novartis | 2 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $32 |
| Bayer | 1 | $23 |
| Sanofi | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $21 |
| Aurobindo Pharma USA, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Secura Bio, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUVENT$183
- MI CANCER SEEK$156
- OPDIVO$125
- RYTELO$123
- Venclexta$116
How this compares
$2,593 in reported general payments places this provider in the 65th percentile of 42 hematology & oncology providers in Hawaii.
Other hematology & oncology in Honolulu
- Tamie KernsHonolulu$48K
- David TamuraHonolulu$31K
- Melvin PalalayHonolulu$20K
- Ryon NakasoneHonolulu$20K
- Arnold YeeHonolulu$17K
- Jared AcobaHonolulu$15K
- Swaty AroraHonolulu$15K
- William LouiHonolulu$12K
- Jodi KagiharaHonolulu$7K
- Nicolas VillanuevaHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.